Spun out of Transposagen Inc., - itself an SBIR involved firm - Hera Biolabs, Inc., is a pre-clinical contract research organization [CRO] utilizing cutting-edge gene-editing technologies to create novel in vivo models for oncology. Organzied around accelerating cancer research and drug development, the firm focuses on rat models to deliver translationally-relevant, high-quality results. Using proprietary technologies, Hera built the SRG⢠Platform, a double knockout Sprague-Dawley rat engineered for T-cell, B-cell, and NK cell deficiency. The firm's first SRG model is the OncoRat®, uniquely suited for xenograft studies given its excellent tumor take-rates and ability to deliver masses 10x that of mouse models in half the time â all without the increased risk of genetic drift from multiple passages as observed in mice.To facilitate immuno-oncology studies, a humanized SRG Model â the ImmunoRat⢠â is in development. The firm also use their proprietary Cas-CLOVER⢠CRISPR System and piggyBac⢠gene-editing technologies and know-how to expand a robust pipeline of animal models
